Evogene's CEO to present at H.C. Wainwright Global Investment Conference 2025.
PorAinvest
jueves, 28 de agosto de 2025, 7:06 am ET1 min de lectura
EVGN--
The presentation will highlight Evogene's new strategic focus on leveraging ChemPass AI to address key challenges in small molecule discovery and optimization. By utilizing its tech-engine, Evogene aims to increase the probability of success while reducing time and development costs. The company's powerful tech-engine drives product innovation through strategic partnerships and collaborations, as well as through its internal proprietary product pipelines [2].
Haviv will be available for one-on-one meetings with interested investors and companies attending the conference. The event provides an opportunity for attendees to gain insights into Evogene's innovative approach to small molecule discovery and optimization, and to discuss potential collaboration opportunities [1][2].
References:
[1] https://www.stocktitan.net/news/EVGN/evogene-to-present-at-h-c-wainwright-27th-annual-global-investment-rv446tvcm7no.html
[2] https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
Evogene Ltd. announced that CEO Ofer Haviv will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. Haviv will highlight the company's new strategic focus on maximizing the value of ChemPass AI, a generative AI tech-engine for small molecule discovery and optimization in pharmaceuticals and agriculture. The presentation is scheduled for September 10, 2025, at 1:00 PM ET, and Haviv will be available for one-on-one meetings.
Evogene Ltd. (NASDAQ: EVGN) has announced that CEO Ofer Haviv will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. Haviv's presentation, scheduled for September 10, 2025, at 1:00 PM ET, will focus on the company's strategic shift towards maximizing the value of ChemPass AI, a proprietary generative AI tech-engine for small molecule discovery and optimization in pharmaceuticals and agriculture [1][2].The presentation will highlight Evogene's new strategic focus on leveraging ChemPass AI to address key challenges in small molecule discovery and optimization. By utilizing its tech-engine, Evogene aims to increase the probability of success while reducing time and development costs. The company's powerful tech-engine drives product innovation through strategic partnerships and collaborations, as well as through its internal proprietary product pipelines [2].
Haviv will be available for one-on-one meetings with interested investors and companies attending the conference. The event provides an opportunity for attendees to gain insights into Evogene's innovative approach to small molecule discovery and optimization, and to discuss potential collaboration opportunities [1][2].
References:
[1] https://www.stocktitan.net/news/EVGN/evogene-to-present-at-h-c-wainwright-27th-annual-global-investment-rv446tvcm7no.html
[2] https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios